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permission from the journal.Objective: Concomitant treatment with angiotensin-
converting enzyme (ACE) inhibitors and dipeptidyl
peptidase-4 (DPP-4) inhibitors is increasingly common.
Pharmacological studies have suggested a potential
adverse drug interaction between ACE inhibitors and DPP-
4 inhibitors resulting in unfavorable hemodynamic
changes; very few studies have examined such an
interaction between angiotensin II receptor blockers (ARBs)
and DPP-4 inhibitors. We investigated blood pressure (BP)
and heart rate (HR) during treatment with the DPP-4
inhibitor linagliptin in individuals receiving either ACE
inhibitors or ARBs in the MARLINA-T2D trial.
Methods: In this study, 360 individuals with type 2 diabetes
and albuminuria receiving unchanged doses of ACE inhibitors
or ARBs were randomized to linagliptin or placebo. Twenty-
four-hour ambulatory BP monitoring, an exploratory
endpoint, was conducted at baseline and after 24 weeks.
Results: Ambulatory BP monitoring data were available for
208 individuals (linagliptin: n¼111; placebo: n¼97).
Baseline mean SD 24-h SBP and DBP were
132.512.4mmHg and 75.99.4mmHg, respectively;
mean 24-h HR was 76.310.1 bpm. At week 24, no
overall effect of the DPP-4 inhibitor versus placebo was
seen on mean 24-h SBP, DBP, or HR. Furthermore, in the
subgroups receiving either an ACE inhibitor or an ARB, no
effect on these hemodynamic parameters was seen as a
result of concomitant DPP-4 inhibitor treatment.
Conclusion: Adding linagliptin to treatment with ACE
inhibitors or ARBs was not associated with any
hemodynamic changes, supporting their concomitant use
in individuals with type 2 diabetes and albuminuria.
Keywords: ambulatory, angiotensin-converting enzyme
inhibitors, AT1 antagonists, blood pressure, blood pressure
monitoring, dipeptidyl-peptidase IV inhibitors, drug
interaction, heart rate
Abbreviations: ABPM, ambulatory blood pressure
monitoring; ACE, angiotensin-converting enzyme; ARB,
angiotensin II receptor blocker; CI, confidence interval;
DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular
filtration rate; MedDRA, Medical Dictionary for Regulatory
Activities; NPY, neuropeptide Y; T2D, type 2 diabetes;
UACR, urinary albumin-to-creatinine ratio1294 www.jhypertension.comINTRODUCTIOND
iabetes affects an estimated 30 million people in
the United States [1] and 415 million individuals
globally [2], most commonly type 2 diabetes (T2D)
(90–95% of cases [1]). T2D is frequently associated with
conditions such as hypertension, chronic kidney disease
and heart failure [3–5], which are often treated with drugs
that interrupt the renin–angiotensin system (RAS), includ-
ing angiotensin-converting enzyme (ACE) inhibitors or
angiotensin II receptor blockers (ARBs).
Consequently, as a result of the epidemic of T2D
and its associated comorbidities, a large number of
individuals currently receive concomitant treatment
with RAS blockers such as ACE inhibitors and dipeptidyl
peptidase-4 (DPP-4) inhibitors, a class of frequently
prescribed oral glucose-lowering drugs [6]. DPP-4 inhib-
itors reduce blood glucose levels mainly by inhibiting
enzymatic degradation of glucagon-like peptide-1, a
major substrate of DPP-4 that stimulates glucose-depen-
dent insulin secretion. However, DPP-4 also has other
peptide substrates, some of which are vasoactive such
as substance P. Furthermore, DPP-4 is largely responsibleDOI:10.1097/HJH.0000000000002032
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Hemodynamics of linagliptin/renin–angiotensin system blockersfor the inactivation of substance P when ACE is inhibited
[7,8].
An adverse hemodynamic interaction between DPP-4
inhibitors and ACE inhibitors has been postulated based on
pharmacological studies in which increases in blood pres-
sure (BP) and heart rate (HR) manifested during concomi-
tant treatment with ACE inhibitors and experimental (P32/
98) or licensed DPP-4 inhibitors (sitagliptin) [9,10]. The
need for further studies in this area was highlighted recently
[11]. Furthermore, there appears to be little data on potential
hemodynamic interactions between DPP-4 inhibitors and
ARBs. Consequently, we explored the potential hemody-
namic effects of another licensed DPP-4 inhibitor, linaglip-
tin, in individuals with T2D and renal disease as reflected by
the presence of microalbuminuria or macroalbuminuria
who were receiving concomitant treatment with ACE inhib-
itors or ARBs.
METHODS
This was a prespecified, exploratory analysis of a 24-week,
randomized, double-blind, placebo-controlled, multina-
tional clinical trial of linagliptin conducted in individuals
with T2D and renal dysfunction (MARLINA-T2D; Clinical-
Trials.gov: NCT01792518).
MARLINA-T2D was designed to investigate the glycemic
and albuminuric effects of linagliptin; the full study method-
ology and main results are described in detail elsewhere
[12,13]. In brief, individuals with T2Ds were eligible to
participate if they were aged 18–80 years with glycated
hemoglobin A1c levels of 6.5–10.0%, BMI of 40kg/m2 or
less, estimated glomerular filtration rate (eGFR) at least
30ml/min per 1.73m2, and were either drug-naı¨ve or receiv-
ing up to two oral glucose-lowering drugs and/or basal
insulin. Individuals were also required to have albuminuria,
manifesting as urinary albumin-to-creatinine ratio (UACR) of
30–3000mg/g, or albuminuriamore than 30mg/l of urine, or
urinary albumin excretion rate more than 30mg/min clearly
documented in the previous 12 months or detected at
screening. Albuminuria had to be confirmed prior to ran-
domization with a geometric mean UACR of 30–3000mg/g
from three consecutive morning urine samples collected 14–
16 days before randomization. Eligible individuals must also
have been receiving a stable (unchanged) dose of an ACE
inhibitor or ARB for at least the ten preceding weeks.
Following a two-week placebo run-in period, partici-
pants were randomized to receive double-blind, once-daily
oral treatment with linagliptin 5mg or placebo for 24
weeks. In an exploratory analysis, changes from baseline
in mean 24-h SBP, mean 24-h DBP, and mean 24-h HR – all
recorded using ambulatory BP monitoring (ABPM) – were
assessed at baseline and after 24 weeks of treatment. These
endpoints were analyzed in the treated set of participants
(those who received at least one dose of study drug) using
an analysis of covariance. ABPM values measured after the
start of glycemic rescue therapy or after a change in anti-
hypertensive treatment were not included in the analysis.
Post-hoc analyses were conducted for changes in ethnic
subgroups (Asian/non-Asian) and changes in the day or
night separately; for the latter, day and night were defined
as 0601–2159 h and 2200–0600 h, respectively.Journal of HypertensionSafety analyses were performed as previously described
[13]. Adverse events of relevance to the current analysis
were defined as those in the vascular disorders system
organ class from the Medical Dictionary for Regulatory
Activities (MedDRA) version 18.1, as well as hypersensitiv-
ity reactions (MedDRA 18.1 Standardized MedDRA Query),
and cardiovascular events adjudicated by a blinded, exter-
nal clinical event committee.
RESULTS
Of the 360 participants in the treated set, ABPM data were
available at baseline for 298 individuals (linagliptin:
n¼ 155; placebo: n¼ 143). At baseline, mean SD 24-h
SBP, 24-h DBP, and 24-h HR were 132.7 12.9 mmHg,
75.9 9.1 mmHg and 77.3 10.4 bpm, respectively
(Table 1). These and other mean baseline characteristics
were similar in the 208 participants (linagliptin: n¼ 111;
placebo: n¼ 97) with ABPM data at both baseline and week
24 (Table 1).
At week 24, there were no significant placebo-adjusted
changes from baseline in mean 24-h SBP, 24-h DBP, or 24-h
HR in individuals treated with linagliptin (Fig. 1). There was
no significant difference between the predominant ethnic
group (Asians) and other (non-Asian) participants in these
parameters: P values for treatment interaction with race were
0.7035, 0.8149, and 0.4196 for mean change from baseline in
24-h SBP, 24-h DBP, and 24-h HR respectively (Fig. S1,
Supplemental Digital Content, http://links.lww.com/HJH/
B54). There was also no significant treatment difference in
changes in mean 24-h SBP, 24-h DBP, or 24-h HR within the
day or night periods separately (Fig. S2, Supplemental Digital
Content, http://links.lww.com/HJH/B54).
Backgroundantihypertensivemedicationwasunchanged
throughout the study in the large majority of participants:
only 7.2 and 5.7% of the linagliptin and placebo groups,
respectively, had a change in dose, and only 9.4 and 8.6%,
respectively, started a new antihypertensive medication.
In subgroups based on the type of RAS blocker received,
the placebo-adjusted change from baseline in mean 24-h SBP
at week 24 with linagliptin was 2.30mmHg [95% confi-
dence interval (CI) 7.43, 2.84; P¼ 0.3789] in participants
receiving ACE inhibitors and 0.90mmHg (95%CI2.32, 4.11;
P¼ 0.5825) in those receiving ARBs (Fig. 2). For mean 24-h
DBP, the placebo-adjusted change from baseline at week 24
was 0.61mmHg (95% CI 3.41, 2.20; P¼ 0.6712) in par-
ticipants taking ACE inhibitors and 0.20mmHg (95% CI
1.57, 1.96; P¼ 0.8260) in those taking ARBs (Fig. 2). The
placebo-adjusted change from baseline in mean 24-h HR at
week 24 was 0.46bpm (95% CI 3.16, 2.24; P¼ 0.738) in
participants receiving ACE inhibitors and 1.29bpm (95% CI
0.40, 2.98; P¼ 0.135) in those receiving ARBs (Fig. 2).
The overall incidence of adverse events was similar
between the linagliptin and placebo groups, with few
participants experiencing vascular disorders, hypersensitiv-
ity reactions or cardiovascular events (Table 2).DISCUSSION
In this prespecified exploratory analysis of the MARLINA-
T2D study, treatment with the DPP-4 inhibitor linagliptinwww.jhypertension.com 1295
TABLE 1. Baseline demographic and clinical characteristics
Treated seta 24-h ABPM populationb
Linagliptin, n¼182 Placebo, n¼178 Linagliptin, n¼111 Placebo, n¼97
Age (years) 61.010.0 60.19.3 61.29.7 60.79.6
Male, n (%) 116 (63.7) 113 (63.5) 74 (66.7) 63 (64.9)
Race, n (%)
Asian 117 (64.3) 122 (68.5) 79 (71.2) 71 (73.2)
White 56 (30.8) 53 (29.8) 29 (26.1) 24 (24.7)
Black/African-American 8 (4.4) 3 (1.7) 2 (1.8) 2 (2.1)
Hawaiian/Pacific Islander 1 (0.5) 0 (0.0) 1 (0.9) 0 (0.0)
BMI (kg/m2) 28.34.8 28.64.9 27.84.5 28.64.9
Weight (kg) 78.118.6 77.919.3 76.417.5 77.518.4
HbA1c, % (mmol/mol) 7.810.87 (61.99.5) 7.870.88 (62.59.6) 7.830.80 (n/a) 7.880.82 (n/a)
Time since diagnosis of diabetes, n (%)
1 year 11 (6.0) 8 (4.5) 4 (3.6) 3 (3.1)
>1–5 years 26 (14.3) 41 (23.0) 17 (15.3) 23 (23.7)
>5–10 years 47 (25.8) 56 (31.5) 27 (24.3) 32 (33.0)
>10 years 98 (53.8) 73 (41.0) 63 (56.8) 39 (40.2)
eGFR (CKD-EPI, cystatin C) (ml/min per 1.73m2) 102.849.7 94.443.3 104.1752.53 92.3244.37
eGFR (CKD-EPI, cystatin C) (ml/min per 1.73m2), n (%)
90 98 (53.8) 88 (49.4) 58 (52.3) 47 (48.5)
60–<90 54 (29.7) 48 (27.0) 35 (31.5) 28 (28.9)
30–<60 25 (13.7) 39 (21.9) 15 (13.5) 20 (20.6)
<30 5 (2.7) 3 (1.7) 3 (2.7) 2 (2.1)
UACR (mg/g) gMeangCV 120.8152.9 131.8165.8 117.1147.5 150.1163.9
UACR (mg/g), n (%)
<30 11 (6.0) 10 (5.6) 6 (5.4) 4 (4.1)
30–<300 134 (73.6) 128 (71.9) 85 (76.6) 68 (70.1)
300 35 (19.2) 37 (20.8) 20 (18.0) 25 (25.8)
Missing data 2 (1.1) 3 (1.7) 0 (0) 0 (0)
SBP (mmHg) 135.113.8 134.613.7 134.513.6 134.312.9
Mean 24-h SBP (mmHg) 131.812.6c 133.713.1d 131.612.4 133.512.3
DBP (mmHg) 77.39.0 78.68.3 76.09.2 79.07.6
Mean 24-h DBP (mmHg) 74.89.1c 77.09.0d 74.49.4 77.59.2
Heart rate (bpm) 75.010.9 75.610.9 74.111.0 76.19.7
Mean 24-h heart rate (bpm) 76.910.4c 77.810.3d 76.010.9 76.69.2
Antihypertensive therapy, n (%) 182 (100.0) 178 (100.0) 111 (100.0) 97 (100.0)
ARBs 120 (65.9) 120 (67.4) 81 (73.0) 69 (71.1)
ACE inhibitors 62 (34.1) 58 (32.6) 30 (27.0) 28 (28.9)
Calcium antagonists 79 (43.4) 88 (49.4) 54 (48.6) 50 (51.5)
Diuretics 52 (28.6) 54 (30.3) 29 (26.1) 29 (29.9)
b-Blockers 40 (22.0) 47 (26.4) 25 (22.5) 25 (25.8)
Other 11 (6.0) 15 (8.4) 7 (6.3) 9 (9.3)
Oral glucose-lowering monotherapy, n (%) 66 (36.3) 67 (37.6) 41 (36.9) 35 (36.1)
Metformin 61 (33.5) 64 (36.0) 37 (33.3) 33 (34.0)
Oral glucose-lowering combination therapy without insulin, n (%) 42 (23.1) 48 (27.0) 23 (20.7) 25 (25.8)
Insulin, n (%) 64 (35.2) 49 (27.5) 41 (36.9) 27 (27.8)
Data are mean SD unless otherwise stated. ABPM, ambulatory blood pressure monitoring; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker;
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; gCV, geometric coefficient of variation; gMean, geometric mean; HbA1c,
glycated hemoglobin A1c; n/a, not available; UACR, urinary albumin-to-creatinine ratio.
aAll randomized participants who received at least one dose of study drug.
bAll participants in the treated set with ABPM data at both baseline and week 24.
cn¼155.
dn¼143.
Cooper et al.added to stable doses of ACE inhibitors or ARBs was not
associated with changes in BP or HR in individuals with
T2D and albuminuria.
A potential adverse hemodynamic interaction between
DPP-4 inhibitors and ACE inhibitors was initially reported
from pharmacological studies [9,10]. In the spontaneously
hypertensive rat model, acute administration of an experi-
mental DPP-4 inhibitor (P32/28) increased BP in animals
pretreated with the ACE inhibitor captopril [9]. Conversely,
in a randomized, placebo-controlled, cross-over study in 24
individuals with metabolic syndrome who were pretreated
for 5 days with sitagliptin, a licensed DPP-4 inhibitor, the1296 www.jhypertension.comhypotensive response to an acute high dose (10 mg) of
enalapril was attenuated, but not to a low dose (5 mg) of
enalapril. Sitagliptin treatment alone led to a mild hypoten-
sive response. Furthermore, only high-dose enalapril
increased HR and plasma norepinephrine concentration
[10]. The authors suggested that the mild hypotensive
response to DPP-4 inhibition might be mediated in part
by the attenuation of substance P metabolism. They further
suggested that during combined high-dose ACE inhibition
and DPP-4 inhibition, activation of the sympathetic nervous
system by substance P and decreased degradation of
neuropeptide Y (NPY)1–36 may offset the decreasedVolume 37  Number 6  June 2019
FIGURE 1 Change from baseline in mean 24-h SBP, DBP, and heart rate at week 24. Analysis of covariance model includes baseline mean 24-h SBP, baseline log10
(urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment as a fixed effect, yanalysis of covariance model includes baseline
mean 24-h DBP, baseline log10 (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment as a fixed effect,
zanalysis of
covariance model includes baseline mean 24-h heart rate, baseline log10 (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and
treatment as a fixed effect. CI, confidence interval.
Hemodynamics of linagliptin/renin–angiotensin system blockersdegradation of vasodilatory peptides [10]. The vasodilatory
substance P is normally inactivated via proteolytic cleavage
by ACE in vivo – however, in the absence of ACE activity,
substance P is inactivated by DPP-4 [7,8]. Subsequently, the
same group reported that exogenous substance P increased
sympathetic activity during acute treatment with both enal-
april and sitagliptin in a randomized, double-blind, pla-
cebo-controlled, cross-over study in 12 healthy individuals
[14]. The vasoconstrictive NPY1–36 is inactivated to NPY3–36
by DPP-4. In a study in the spontaneously hypertensive rat
model, sitagliptin had prohypertensive effects that were
mediated by NPY1–36, and the latter was shown to elicit
potent vasoconstriction in the kidneys [15].
There are several possible reasons for the divergent
findings between these previous studies and our observa-
tions on the hemodynamic effects of combined DPP-4 and
ACE inhibition. First, the previous studies only investigated
the acute or short-term treatment effect, whereas individu-
als in the MARLINA-T2D study were treated with the com-
bination of linagliptin and either an ACE inhibitor or ARBJournal of Hypertensionfor 24 weeks. It is unclear whether transient initial increases
in BP and HR arising from combined DPP-4 and ACE
inhibition would have clinical relevance in the absence
of long-term changes. Second, unlike the previous studies,
many participants in MARLINA-T2D were receiving other
antihypertensive agents as well as ACE inhibitors, which
may have attenuated increases in BP and HR. For example,
one-quarter of participants were receiving b-blockers. The
antihypertensive polypharmacy seen in MARLINA-T2D is
common in clinical practice, as most individuals with
hypertension require two or more drugs to achieve target
BP, thus highlighting the clinical generalizability of these
findings [16,17]. Third, the increases in BP and HR observed
previously during acute treatment with sitagliptin and enal-
april occurred only with high doses of the latter agent [10]
whereas individuals in our study were treated with lower,
practice-based, ACE inhibitor doses. Fourth, there may be
within-class heterogeneity for interactions between ACE
inhibitors and DPP-4 inhibitors, as the latter comprise
a chemically diverse class of compounds whosewww.jhypertension.com 1297
FIGURE 2 Treatment difference in adjusted mean change from baseline in mean 24-h SBP (a), 24-h DBP (b), and heart rate (c) at week 24 by antihypertensive background
therapy. Treatment difference: difference in the adjusted means for linagliptin versus placebo at week 24; yanalysis of covariance model includes baseline mean 24-h SBP,
baseline log10 (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment as a fixed effect;
zanalysis of covariance model
includes baseline mean 24-h SBP, baseline log10 (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment, angiotensin-
converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker back-
ground therapy at baseline by treatment interaction as fixed effects; §analysis of covariance model includes baseline mean 24-h DBP, baseline log10 (urinary albumin-to-
creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment as a fixed effect; analysis of covariance model includes baseline mean 24-h DBP,
baseline log10 (urinary albumin-to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment, angiotensin-converting enzyme inhibitor/angioten-
sin II receptor blocker background therapy at baseline, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline by treatment
interaction as fixed effects; yyanalysis of covariance model includes baseline mean 24-h heart rate, baseline log10 (urinary albumin-to-creatinine ratio), baseline glycated
hemoglobin A1c as linear covariates and treatment as a fixed effect; zzanalysis of covariance model includes baseline mean 24-h heart rate, baseline log10 (urinary albumin-
to-creatinine ratio), baseline glycated hemoglobin A1c as linear covariates and treatment, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker back-
ground therapy at baseline, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker background therapy at baseline by treatment interaction as fixed
effects. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CI, confidence interval.
Cooper et al.
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TABLE 2. Adverse events
Linagliptin,
n¼182
Placebo,
n¼178
Any adverse event 58.8 60.1
Drug-related adverse event 7.1 6.2
Adverse event leading to discontinuation 1.6 1.1
Serious adverse event 9.3 4.5
Vascular disordersa 3.8 3.9
Hypertension 2.2 2.2
Hypotension 0.5 1.1
Aortic occlusion 0.0 0.6
Ischemic necrosis 0.0 0.6
Hematoma 0.5 0.0
Orthostatic hypotension 0.5 0.0
Hypersensitivity reactionsb 4.4 3.4
Eczema 0.5 1.7
Contact dermatitis 1.1 1.1
Eyelid edema 0.0 0.6
Dermatitis 0.5 0.0
Hypersensitivity 0.5 0.0
Rash 0.5 0.0
Allergic rhinitis 0.5 0.0
Face swelling 0.5 0.0
Cardiovascular eventsc 1.6 0.6
Transient ischemic attack 0.0 0.6
Nonfatal stroke 0.0 0.0
Nonfatal myocardial infarction 0.5 0.0
Hospitalization for unstable angina 0.0 0.0
Cardiovascular death 1.1 0.0
Acute myocardial infarction 0.0 0.0
Sudden death 0.0 0.0
Worsening of heart failure 0.0 0.0
Cardiogenic shock 0.0 0.0
Fatal stroke 0.5 0.0
Ischemic stroke 0.0 0.0
Hemorrhagic stroke 0.5 0.0
Not assessable 0.0 0.0
Other 0.5 0.0
Data are % of participants in the treated set (all randomized participants who received at
least one dose of study drug). Medical Dictionary for Regulatory Activities (MedDRA)
version 18.1 used for reporting.
aSystem organ class from MedDRA 18.1.
bStandardized MedDRA Query from MedDRA 18.1.
cCardiovascular events confirmed after adjudication by an external clinical events
committee.
Hemodynamics of linagliptin/renin–angiotensin system blockerspharmacokinetic properties vary substantially [18]. Whereas
theprevious studies employedanexperimentalDPP-4 inhib-
itor, P32/98 [9], and a widely prescribed member of this drug
class, sitagliptin [10], we evaluated another licensed DPP-4
inhibitor, linagliptin, with a different chemical structure.
Furthermore, a recent post-hoc analysis of the EXAMINE
cardiovascular outcomes study found no increase in cardio-
vascular events in individuals receiving combination treat-
ment with alogliptin, another licensed DPP-4 inhibitor, and
ACE inhibitors [19]. Alogliptin treatment was also not associ-
ated with increased HR or BP as assessed rather crudely by
spot measurements. Mitigating against the possibility of
heterogeneity inDPP-4 inhibitor interactionswithACE inhib-
itors, however, is the fact that all licensed compounds
including sitagliptin, linagliptin and alogliptin have high
affinity for DPP-4, with half-maximal inhibitory concentra-
tion values in the low nanomolar range [20].
The findings of this clinical trial are consistent with
preclinical studies analyzing the combination of an ARBJournal of Hypertension(telmisartan) and linagliptin in a hypertensive diabetic
mouse model [21] and in the 2-kidney 1-clip rat model of
renovascular hypertension [22]. Both studies showed that
the BP-lowering effect of telmisartan was not affected by
concomitant treatment with linagliptin [21,22].
Limitations of this study include the fact that treatment
effects were not evaluated in subgroups based on BMI or
eGFR level, due to low patient numbers in certain of
these subgroups.
In conclusion, this prespecified exploratory analysis of
the MARLINA-T2D clinical trial does not support the exis-
tence of an adverse hemodynamic interaction between
DPP-4 inhibitors, in general, and ACE inhibitors or ARBs.
The lack of an increase in BP or HR observed in our study
suggests that concomitant use of linagliptin with either ACE
inhibitors or ARBs in patients with albuminuric diabetic
kidney disease is safe in this regard. Taken together with the
lack of an increase in cardiovascular events seen in partic-
ipants receiving alogliptin and ACE inhibitors in the EXAM-
INE study [19], our findings suggest that hemodynamic
effects arising from the combination of a DPP-4 inhibitor
and an ACE inhibitor are either limited to the acute setting
or are not a class effect of DPP-4 inhibitors.
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